Loading...
XSHG603896
Market cap599mUSD
Dec 20, Last price  
22.06CNY
1D
-0.68%
1Q
16.35%
Name

Zhejiang Shouxiangu Pharmaceuticl Co Ltd

Chart & Performance

D1W1MN
XSHG:603896 chart
P/E
17.19
P/S
5.58
EPS
1.28
Div Yield, %
1.99%
Shrs. gr., 5y
1.23%
Rev. gr., 5y
8.93%
Revenues
784m
-5.39%
177,752,928253,030,064301,591,563301,912,435314,879,954369,963,314511,451,922546,758,533636,050,563767,137,327829,071,599784,347,256
Net income
254m
-8.39%
34,022,82154,048,12869,251,16462,643,86180,977,81688,879,887107,652,897123,895,326151,712,138200,826,526277,783,036254,480,058
CFO
315m
-7.68%
45,356,80765,849,813102,899,07585,029,30095,516,877110,803,595171,513,111207,918,192256,358,637296,699,128341,283,418315,057,385
Dividend
Jun 20, 20240.39 CNY/sh
Earnings
May 16, 2025

Profile

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale, crocus sativus, and other health products. The company was founded in 1997 and is based in Jinhua, China.
URL
sxg1909.com
IPO date
Employees
Domiciled in
BE
Incorporated in
BE

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
784,347
-5.39%
829,072
8.07%
767,137
20.61%
Cost of revenue
545,937
533,597
532,626
Unusual Expense (Income)
NOPBT
238,410
295,475
234,511
NOPBT Margin
30.40%
35.64%
30.57%
Operating Taxes
431
453
749
Tax Rate
0.18%
0.15%
0.32%
NOPAT
237,979
295,022
233,762
Net income
254,480
-8.39%
277,783
38.32%
200,827
32.37%
Dividends
(92,780)
(60,317)
(45,886)
Dividend yield
1.47%
0.79%
0.53%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
372,161
277,846
5,632
Long-term debt
388,129
444,532
114,260
Deferred revenue
49,984
41,298
38,225
Other long-term liabilities
1
1
Net debt
(809,387)
(866,137)
(688,092)
Cash flow
Cash from operating activities
315,057
341,283
296,699
CAPEX
(414,540)
Cash from investing activities
(1,298,783)
Cash from financing activities
290,081
335,839
FCF
165,960
153,847
122,748
Balance
Cash
1,503,962
1,554,712
807,984
Long term investments
65,714
33,802
Excess cash
1,530,459
1,547,061
769,627
Stockholders' equity
1,370,363
1,049,276
766,581
Invested Capital
1,587,228
1,595,735
994,149
ROIC
14.95%
22.78%
24.18%
ROCE
8.05%
11.16%
13.29%
EV
Common stock shares outstanding
195,754
192,543
193,587
Price
32.24
-18.71%
39.66
-11.12%
44.62
65.14%
Market cap
6,311,105
-17.35%
7,636,249
-11.60%
8,637,872
73.44%
EV
5,602,650
6,770,113
7,996,922
EBITDA
314,633
359,852
288,408
EV/EBITDA
17.81
18.81
27.73
Interest
25,048
13,028
10,170
Interest/NOPBT
10.51%
4.41%
4.34%